Sana Biotechnology opened lower at $2.25, compared with its previous close of $2.29. In the last trading session, the stock traded between $2.00 and $2.25. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Sana Biotechnology is now worth
$ 9.21
Resulting in a loss of
$ 90.79 (90.79%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.29 (-12.45%)
Day High
$2.25
Day Low
$2.00
Day Open
$2.25
Prev Close
$2.29
Volume
31,65,141
1W Return
-21.46%
1M Return
-23.62%
3M Return
-47.17%
6M Return
-43.68%
1Y Return
-52.71%
Fundamentals
Market Cap ($ Mn)
601
PE Ratio
-
PB Ratio
7.61
PEG Ratio
-
ROE
-130.11%
ROCE
-64.11%
EPS (TTM)
$0.07
Investment Returns
1 Week
-21.46%
1 Month
-23.62%
3 Months
-47.17%
6 Months
-43.68%
9 Months
-48.32%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
Sana Biotechnology Q3 Results: Adjusted loss narrows to $0.14 per share
Adjusted loss per share narrowed to $0.14 in Q3. Result beat analyst consensus estimate of $0.15 by 6.67%. Losses improved 6.67% compared to $0.15 in same period last year.
7 days ago
11Aug
Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027
Sana Biotechnology delivered better-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) beating consensus. The firm raised $93.3 million, boosting cash to $160.5 million and extending its runway to mid-2027. Key developments include progress toward Phase 1/2 trials for SC451 and SG293, a strategic partnership with Mayo Clinic involving a $25 million investment, and reduced operating cash burn.
3mo ago
29Jul
Halper Sadeh probes Sana Biotechnology for fiduciary breaches
Halper Sadeh LLC investigates Sana Biotechnology, Inc. insiders for potential fiduciary duty breaches. The firm seeks shareholder input to pursue governance reforms and financial relief. Long-term investors are urged to contact the firm regarding their legal rights and options on a contingent fee basis.
3mo ago
13Jul
Sana Biotechnology highlights durable islet cell function in NEJM
Sana Biotechnology, Inc. announced publication of 14-month data in The New England Journal of Medicine for UP421, showing durable insulin production without immunosuppression. The study confirmed cell survival and safety via C-peptide levels and PET-MRI scanning. Sana plans to file an IND for SC451 and start a Phase 1/2 trial this year.
4mo ago
2Jul
Sana Biotechnology to present UP421 data at EASD 2026
Sana Biotechnology, Inc. (NASDAQ: SANA) announced it will present clinical data from an investigator-sponsored, first-in-human study of UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform (HIP) technology, at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. The study evaluates the therapy in a type 1 diabetes patient without immunosuppression, aiming to reduce immune rejection risks.
